Oct 12, 2026
Upcoming clinical, regulatory, and commercial milestones could reignite these battered biotech stocks—but investors must weigh triple-digit potential against significant development risks.
Oct 11, 2026
Tilray is building momentum through booming beverage sales and expanding international medical cannabis operations. Its growth strategy is gaining traction without relying on U.S. legalization.
Oct 10, 2026
A 16% pullback has little to do with InvenTrust’s solid operating performance and growing dividend. With analysts seeing nearly 18% upside, the REIT may offer an attractive entry point—provided investors can stomach rising leverage.
Oct 9, 2026
Disney is licensing select titles to Netflix to turn reach into revenue, signaling a new era of flexible exclusivity. The deal shows how cash flow—not platform control alone—is reshaping streaming.
Oct 8, 2026
Curaleaf’s 25% richer offer for Aurora Cannabis intensifies the race to consolidate the sector’s undervalued assets. With Schedule III tax relief reshaping cannabis economics, investors are watching whether strategic acquisitions can unlock a broader industry turnaround.
Oct 7, 2026
Insiders are cashing in on Aspen Aerogels, Workday, and Everpure—but strong business results could mean their sales aren’t a warning sign. Here’s what investors should know before following suit.
Oct 6, 2026
As AI compute prices threaten data-center returns, the real opportunity may lie with companies solving the industry’s power bottleneck. These four energy stocks offer faster access to electricity through behind-the-meter generation and geothermal technology.
Oct 5, 2026
Strong sales and ambitious expansion are colliding with rising debt, thin margins, and a battered stock price. Upcoming earnings and Investor Day could determine whether First Watch is a bargain—or a warning sign.
Oct 4, 2026
McDonald’s stock has plunged into deeply oversold territory, but AI-pricing concerns and key support levels could determine whether this is a buying opportunity—or a falling knife.
Oct 3, 2026
The $5.7 billion award won’t threaten Apple’s balance sheet—but a recurring royalty on iPhones and Apple Watches could squeeze margins for years. Investors are watching the appeal closely.
Oct 2, 2026
Shares are down 19% despite solid earnings, accelerating professional sales and a bullish long-term outlook. But a premium valuation and softer DIY traffic leave investors weighing quality against risk.
Oct 1, 2026
A record $150 billion buyback highlights NVIDIA’s confidence in its cash flow and could amplify long-term shareholder returns. With AI demand still expanding, analysts see substantial upside ahead.
